A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 74 (final count)
- Started
- Nov 8, 2024
- Main results expected
- Aug 2027
- Fully finished
- Aug 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Adverse Events (AE)s
Measured over: Up to a Maximum of 4 Years
Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator
Measured over: Up to a Maximum of 4 Years
Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator
Measured over: Up to a Maximum of 4 Years
Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator
Measured over: Up to a Maximum of 4 Years
Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to a Maximum of 4 Years
Overall Survival (OS)
Measured over: Up to a Maximum of 4 Years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06614192 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC